Safety and efficacy of vedolizumab versus TNFa antagonists in an elderly patients with inflammatory bowel disease: A retrospective cohort study
Latest Information Update: 23 Jul 2021
Price :
$35 *
At a glance
- Drugs Vedolizumab (Primary) ; Adalimumab; Golimumab; Infliximab; Tumour necrosis factor alpha inhibitors
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions
- 15 Jul 2021 Results published in the Digestive Diseases and Sciences
- 22 Dec 2020 New trial record
- 28 Oct 2020 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2020